Evidence map›Paper›PMID 33964442›Full record

ArticleBioorganic & medicinal chemistry letters2021

Structural understanding of 5-(4-hydroxy-phenyl)-N-(2-(5-methoxy-1H-indol-3-yl)-ethyl)-3-oxopentanamide as a neuroprotectant for Alzheimer's disease.

John Saathoff, Jakob Green, Yuqi Jiang, Yiming Xu, Glen E Kellogg, Shijun Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

John SaathoffDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Jakob GreenDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Yuqi JiangDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Yiming XuDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Glen E KelloggDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Shijun ZhangDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: szhang2@vcu.edu.
Virginia Commonwealth University · US

Funding

Development of NLRP3 inflammasome inhibitors towards Alzheimer's diseaseR01AG058673 · NIA · VIRGINIA COMMONWEALTH UNIVERSITY · PI SUN, DONG, WANG, XIANG-YANG SHAWN · 2018 to 2020
$2.3M
NIA NIH HHS R01 AG058673
6 · The paper itself

Abstract

In our continuing efforts to develop novel neuroprotectants for Alzheimer's disease (AD), a series of analogs based on a lead compound that was recently shown to target the mitochondrial complex I were designed, synthesized and biologically characterized to understand the structure features that are important for neuroprotective activities. The results from a cellular AD model highlighted the important roles of the 4-OH on the phenyl ring and the 5-OCH

Indexed as

Alzheimer DiseaseCell LineDose-Response Relationship, DrugHumansMolecular StructureNeuroprotective AgentsStructure-Activity RelationshipNeuroprotective AgentsAlzheimer’s diseaseFMN binding siteMitochondrial complex IStructural modification

Identifiers

PMID33964442
PMCPMC8187328
OpenAlexW3158105757

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.